Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT
Key facts
- Where
- Hat Yai, ThailandSee the site
Where in Thailand
- Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla UniversityHat Yai, ThailandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Prince of Songkla University
- Trial code
- NCT03648814
- Record updated
- 21 August 2025
- Original description
To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.Read full original descriptionShow less
Efficacy and Safety of Intracameral Versus Intravitreal Bevacizumab Injection as an Adjunctive Therapy Before Trabeculectomy With Mitomycin-C in Neovascular Glaucoma: A Prospective Randomized Trial
To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.
Inclusion: Diagnosis of neovascular glaucoma; The patients having IOP > 21 mmHg, having the indication for trabeculectomy; The patients' age of at least 18-year-old; The patients having visual potential at least hand motion; Present of NVI or NVA; Willing and able to provide informed consent to participate in the study; Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits.
Exclusion: History of bevacizumab or fluorescence dye allergy; Active infectious ocular disease including endophthalmitis and corneal ulcer; History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension; Cannot obtain endothelial cell count; One eye patient; Patients having severe corneal edema or total hyphema obscure NVI or NVA view; Has or planning to be pregnant or breastfeeding.